focus -WSS

focus

author：focus 2025-08-23 04:57:00 - browse：4993

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medicare details structure of new drug price negotiation program
Next article： Setback for rare diseases as Taysha Gene Therapies pulls back

knowledge

WSS

CDC picks Alphabet's Verily for wasterwater surveillance contract

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Readout Newsletter: New research from Sanofi, Regeneron, etc.

With Roe v Wade overturned, abortion providers work to adapt

Readout Newsletter: What happened with Sarepta's Duchenne data

WHO recommends second malaria vaccine

leisure time

focus

explore

Malaria cases in Florida and Texas: Here’s what you need to know

WHO may add ‘noma' to its list of neglected tropical diseases

Virginia high school admissions case could be legal follow

With Roe v Wade overturned, abortion providers work to adapt

Drug repurposing or repositioning? The language matters

Meta's Zuckerberg and Chan on track to put $50 billion into science

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What we owe ALS patients — and why one company fell short

After affirmative action ruling, medical educators look to 'holistic review'

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

explore

The biotech scorecard for Q4: 16 stock

Stop Congress from blocking public access to science

Flu, Covid vaccination rates decline, new survey data show

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

CDC picks Alphabet's Verily for wasterwater surveillance contract

Flu, Covid vaccination rates decline, new survey data show

Wikipedia

knowledge

focus

focus